Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Cardiovascular Systems (CSII) Share Price

News headlines about Cardiovascular Systems (NASDAQ:CSII) have trended somewhat positive recently, Accern reports. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cardiovascular Systems earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave news coverage about the medical device company an impact score of 47.0383848014793 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the news articles that may have impacted Accern’s rankings:

Several equities analysts have commented on the stock. Zacks Investment Research cut shares of Cardiovascular Systems from a “buy” rating to a “hold” rating in a research report on Monday. Leerink Swann dropped their target price on shares of Cardiovascular Systems from $31.00 to $30.00 and set an “outperform” rating on the stock in a research report on Thursday, February 8th. BidaskClub cut shares of Cardiovascular Systems from a “hold” rating to a “sell” rating in a research report on Friday, February 2nd. ValuEngine cut shares of Cardiovascular Systems from a “hold” rating to a “sell” rating in a research report on Friday, February 2nd. Finally, William Blair reissued a “market perform” rating on shares of Cardiovascular Systems in a research report on Thursday, December 21st. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $27.00.

Shares of Cardiovascular Systems (NASDAQ:CSII) opened at $22.50 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.83 and a current ratio of 4.65. Cardiovascular Systems has a one year low of $20.58 and a one year high of $33.11. The stock has a market cap of $699.24, a P/E ratio of -224.98 and a beta of 2.32.

Cardiovascular Systems (NASDAQ:CSII) last issued its quarterly earnings results on Wednesday, February 7th. The medical device company reported ($0.01) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.04) by $0.03. Cardiovascular Systems had a negative net margin of 1.62% and a negative return on equity of 0.50%. The company had revenue of $52.63 million during the quarter, compared to analyst estimates of $53.39 million. During the same quarter last year, the business posted $0.03 EPS. Cardiovascular Systems’s quarterly revenue was up 5.2% compared to the same quarter last year. research analysts expect that Cardiovascular Systems will post -0.07 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This article was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/16/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-cardiovascular-systems-csii-share-price.html.

Cardiovascular Systems Company Profile

Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.

Insider Buying and Selling by Quarter for Cardiovascular Systems (NASDAQ:CSII)

Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply